Current market catalysts

8-K filing — PLAINS ALL AMERICAN PIPELINE LP (PAAPU)

Filed: 2026-09-09 AccNo: 0001104659-26-105984 Size: 304 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Top Stock Picks for Week of September 7, 2026

Zacks highlights two Strong Buy stocks: Bloom Energy (BE), a renewable energy company with improved earnings outlook and strong technical momentum, and Abercrombie & Fitch (ANF), a specialty retailer benefiting from sales growth, inventory management, and raised fiscal 2026 guidance.

CrowdStrike vs. OKTA: What Revenue Trends Between These Cybersecurity Giants Tell Investors

CrowdStrike and OKTA both show strong quarter-over-quarter revenue growth driven by increased AI-related cybersecurity demand. CrowdStrike's revenue nearly doubled over eight quarters ($1.0B to $1.5B), significantly outpacing OKTA's steady growth ($665M to $805M). However, OKTA is profitable with a 13% operating margin, while CrowdStrike remains unprofitable at -2%. CrowdStrike commands a premium valuation (P/S ratio of 38) versus OKTA's more reasonable multiple (P/S of 10), making OKTA potentially better value for investors despite CrowdStrike's faster growth trajectory.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Wolfspeed, Inc. - WOLF

Pomerantz LLP is investigating potential securities fraud claims against Wolfspeed, Inc. following the company's disappointing Q4 2026 earnings report on August 19, 2026. Wolfspeed reported revenue of $149.6 million, significantly missing the consensus estimate of $223.55 million, and posted an adjusted loss of $2.26 per share versus the expected $0.52 per share. The stock declined 9.42% to $26.35 per share on August 20, 2026.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the company's announcement on August 17, 2026, that its DURAVYU drug failed to meet primary endpoints in the LUGANO Phase 3 clinical trial for wet AMD treatment. The failure to demonstrate superiority over Regeneron's Eylea resulted in a 66.98% stock price decline, falling from approximately $14.75 to $4.87 per share.

Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons

Major stock indices declined on September 8, 2026, as rising crude oil prices approaching $100/barrel and geopolitical tensions weighed on markets. The Dow fell 1.18%, S&P 500 dropped 0.58%, and Nasdaq declined 0.31%. Notable movers included Intel gaining 9% on pricing plans, Corning rising 7% on a Verizon fiber deal, while Amgen and Novartis fell sharply following a drug trial setback. Qualcomm signed a major AI chip deal with Amazon worth up to $60 billion.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

Pomerantz LLP is investigating potential securities fraud claims against Emergent BioSolutions following the company's August 5, 2026 earnings report. Emergent reported a $191.3 million non-cash impairment charge on its NARCAN asset group, resulting in a $180.2 million net loss, and cut full-year revenue guidance by 10.8%. The company attributed the decline to increased competitive intensity. Emergent's stock price fell 29.58% to $5.31 per share on August 6, 2026.

CCOI IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cogent Communications Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 21 Deadline in Securities Class Action - CCOI

Rosen Law Firm is encouraging investors who suffered losses in Cogent Communications Holdings, Inc. (CCOI), UWM Holdings Corporation (UWMC), and UP Fintech Holding Limited (TIGR) to join securities class action lawsuits. The firm alleges that Cogent made false statements about its optical wavelength backlog and financial capacity, while investigations are ongoing for the other companies. The lead plaintiff deadline for the Cogent case is September 21, 2026.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alibaba Group Holding Limited of Class Action Lawsuit and Upcoming Deadlines – BABA

Pomerantz Law Firm has filed a class action lawsuit against Alibaba Group Holding Limited, alleging securities fraud and unlawful business practices. The lawsuit follows two major negative events: Alibaba's inclusion on the U.S. Department of Defense's list of Chinese military companies (causing a 39% stock price drop on June 10, 2026), and accusations from Anthropic that Alibaba used fraudulent accounts to gain unauthorized access to its Claude AI model (causing a 7.34% price decline on June 25, 2026). Investors have until October 5, 2026, to request Lead Plaintiff status.

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics granted stock options to purchase 4,200 shares to two new employees on September 4, 2026, with an exercise price of $5.72 per share under its 2022 Employment Inducement Award Plan. The options vest 25% on the first anniversary and 6.25% quarterly thereafter.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of L3Harris Technologies, Inc. - LHX

Pomerantz Law Firm is investigating L3Harris Technologies for potential securities fraud following the immediate resignation of Chairman and CEO Christopher Kubasik on August 17, 2026, due to conduct inconsistent with company values. The announcement triggered a 4.61% stock price decline, falling $13.44 per share to $278.38.

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

Pomerantz LLP is investigating potential securities fraud claims against SELLAS Life Sciences Group, Inc. following reports that the company failed to timely release phase 3 clinical trial results for Galinpepimut-S after reaching a pre-specified trigger event (80th patient death). The stock declined 13.15% to $13.21 per share on August 28, 2026, following the news.

Core Scientific Director Purchases 7,000 Shares

Eric Stanton Weiss, a Director at Core Scientific, purchased 7,000 shares on August 18, 2026, at a weighted-average price of $19.19 per share, bringing his total holdings to 259,262 shares. The insider purchase signals confidence in the company's future prospects, particularly given the stock's strong 30% performance over the past 12 months and bullish analyst sentiment with 94% buy ratings and a median price target of $36.

Elastic's 2026 Outlook: AI Search Integration Fuels Enterprise Customer Retention

Elastic (ESTC) has achieved a Superscore of 80 out of 100, reflecting its successful transition to profitability in fiscal 2026 with $368 million in net income. The company's AI-driven products like Search AI and agentic workflows are driving enterprise customer retention and expansion. However, stretched valuation multiples (EV-to-EBITDA of 502x) and intense competition from hyperscalers present risks. The analyst predicts the stock could double by 2031 if the company sustains mid-teens revenue growth and pushes operating margins toward 20%.

17 Education & Technology Group Inc. Announces Second Quarter 2026 Unaudited Financial Results

17 Education & Technology Group Inc. (NASDAQ: YQ) reported Q2 2026 net revenues of RMB90.1 million, a 254.6% year-over-year increase, with gross margin expanding to 69.2%. The company achieved its first quarterly GAAP net profit of RMB1.1 million and adjusted net income of RMB4.7 million, driven by expansion of its AI-powered Yiqi Aixue consumer application and improved operational efficiency. The company maintains a strong cash position of RMB456.9 million.

Here's the One Storage Stock I'd Buy With $2,000

The AI data center boom has driven storage companies to secure multiyear contracts with locked-in pricing and volumes extending into 2027-2029. Western Digital, Seagate, and Sandisk all benefit from this demand surge, but Seagate emerges as the top pick due to its pricing locked for all of 2027 and most capacity allocated through 2028, combined with accelerating 56% year-over-year growth guidance.

Crypto Market Today, Sept. 8: Bitcoin Slides as Fed Hike Odds Pass 60%

Bitcoin fell 0.9% to $78,475 on September 8, 2026, as Federal Reserve rate hike odds exceeded 60% and a Liquid Network hack pressured sentiment. Ethereum showed resilience, declining only 0.1%, buoyed by the Ethereum Foundation's quantum readiness announcement and corporate buying. Solana fell 0.6% amid broader macro caution driven by rising oil prices and rate hike concerns.

Prediction: This AI Power Stock Will Double Revenue Before 2030. Here's the Math.

Vertiv Holdings, a provider of critical digital infrastructure for AI data centers, generated $10.2 billion in revenue in 2025 and is positioned to double that by 2030. Management targets 20-22% annual organic sales growth through 2030, with projected revenue of $26 billion. The company exited 2025 with $15 billion in backlog and faces execution risks related to capacity expansion and sustained demand as the AI infrastructure build-out matures.

17 Education & Technology Q2 Adj. EPS $0.06 Up From $(0.29) YoY, Sales $13.278M Up From $3.547M YoY

Bitcoin Braces For CPI as Oil Nears $100 and ETF Inflows Hit $3.8 Billion

Bitcoin holds near $79,000 as oil and yields rise ahead of U.S. inflation data, while $3.8 billion in ETF inflows provides strong support.

8-K/A filing — Granite Ridge Resources, Inc. (GRNT)

Filed: 2026-09-09 AccNo: 0001928446-26-000062 Size: 141 KB Item 5.07: Submission of Matters to a Vote of Security Holders

8-K filing — Evommune, Inc. (EVMN)

Filed: 2026-09-09 AccNo: 0001193125-26-385430 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Full Transcript: Mission Produce Q3 2026 Earnings Call

Mission Produce (NASDAQ:AVO) held its third-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial

Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of $1.00 trillion.

8-K filing — FOOD CULTURE INC.

Filed: 2026-09-09 AccNo: 0001477932-26-005464 Size: 151 KB Item 8.01: Other Events

Elon Musk Documentary Gets Perfect Score After Film Festival Premiere, Trailer Shows Criticism of ‘Real-Life Iron Man’

A film about Elon Musk that the billionaire doesn't want people to see is getting positive reviews after its world premiere.

Evommune Reveals Top-Line Results From EVO756 Phase 2b Trial In Moderate-To-Severe Atopic Dermatitis; Says Trial Did Not Meet The Primary Endpoint Of Percent Change In Eczema Area And Severity Index Score From Baseline At Week 12; EVO756 Was Generally Well Tolerated; To Continue Phase 2b Development Of EVO756 In Migraine Prophylaxis; Will Not Advance EVO756 In Atopic Dermatitis

Here's How Much $100 Invested In Linde 10 Years Ago Would Be Worth Today

Linde (NASDAQ:LIN) has outperformed the market over the past 10 years by 1.14% on an annualized basis producing an average annual return of 14.78%. Currently, Linde has a market capitalization of $217.97 billion.

8-K filing — TELEFLEX INC (TFX)

Filed: 2026-09-09 AccNo: 0000096943-26-000101 Size: 174 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits